Zejula

Zejula (Niraparib Tosilate Monohydrate) is an oral prescription medication used in cancer treatment. It belongs to the class of PARP inhibitors, supporting targeted therapy. This overview covers general uses and handling notes for informational purposes only.

Zejula is primarily used in the maintenance treatment of certain types of ovarian, fallopian tube, or peritoneal cancers. It may be prescribed after a patient responds to platinum-based chemotherapy. The medication works by helping to slow or stop cancer cell growth. Patients often ask, 'What is Niraparib Tosilate Monohydrate used for?' and this addresses its role in targeted cancer therapy.

Common effects reported with Zejula include mild to moderate gastrointestinal symptoms such as nausea or upset stomach. Some patients may experience fatigue or changes in blood cell counts. These effects are typically monitored by healthcare providers during treatment. Individual responses can vary widely.

Zejula should be handled with care, especially by those who are pregnant or breastfeeding. It is important to store the medication in a secure, dry place away from children. Regular medical check-ups are recommended to monitor treatment progress and any potential side effects.

Zejula may interact with certain other medications, including strong CYP3A4 inhibitors or inducers. Grapefruit products and St. John’s Wort can also affect how the drug works. Always inform your healthcare provider about all medications and supplements you are taking before starting Zejula.